Abstract: The present application relates to a method for preparing an antibody or antibody fragment composition from raw milk from a non-human mammal expressing said antibody or antibody fragment in its milk, comprising steps a) precipitation of the raw milk with caprylic acid, b) separation, consisting of centrifugation or filtration through a depth filter, and optionally c) filtration through an active carbon depth filter.

Abstract: The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNF.alpha.) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in the intestine.

Abstract: The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.

Abstract: The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof.

Abstract: Disclosed is a method for preparing an immunoglobulin (Ig) concentrate useful for treating RSV infection, including a step consisting in subjecting an Ig composition derived from blood plasma to affinity chromatography utilizing an RSV-specific ligand. In a particular embodiment, the RSV-specific ligand is an RSV F protein, preferentially in prefusion conformation, or a variant or an antigenic fragment thereof.

Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Abstract: The present invention concerns an injectable composition comprising FVII and a filler, and its use for preventing or treating body and skin defects, especially folds, wrinkles, skin depressions and scars, while diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.

Abstract: The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof.

Abstract: The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.

Abstract: Disclosed is a copolymer of following formula (I): in which:—x is an integer between 10 and 250, preferably between 40 and 120, —y is an integer between 4 and 100, preferably between 10 and 100, preferably between 19 and 60, —z is an integer between 0 and (100?y), preferably equal to 0, —R represents an alkyl radical having 1 to 10 carbon atoms, a phospholipid, a glycosaminoglycan or an affinity ligand, and —R? represents a hydrogen, the —CH2—C?CH group, a —CH2-1H-1,2,3-triazole group, a —CH2—CH2—CH2—S—R? group, in which R? represents an alkyl radical having 1 to 10 carbon atoms, a phospholipid, a glycosaminoglycan, an affinity ligand or an imaging probe, and the uses of same.

Abstract: The invention relates to a method for preparing plasma protein concentrate from blood plasma by means of multicolumn chromatography.

Abstract: The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.

Abstract: The invention relates to a method for purifying or detecting a target protein present in a solution, wherein said method comprises, before carrying out the purification or detection step itself, the step of contacting said solution with an aptamer binding specifically to said target protein, wherein said aptamer does not bind to any protein homologous to said target protein that could also be present in the solution.

Abstract: The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Abstract: The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.

Abstract: The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.

Abstract: The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Abstract: The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.

Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.